JP2018519342A - ホップに基づく物質およびその物質の使用 - Google Patents
ホップに基づく物質およびその物質の使用 Download PDFInfo
- Publication number
- JP2018519342A JP2018519342A JP2018500292A JP2018500292A JP2018519342A JP 2018519342 A JP2018519342 A JP 2018519342A JP 2018500292 A JP2018500292 A JP 2018500292A JP 2018500292 A JP2018500292 A JP 2018500292A JP 2018519342 A JP2018519342 A JP 2018519342A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- xanthohumol
- substance according
- prevention
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 54
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 claims abstract description 66
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 claims abstract description 65
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 claims abstract description 65
- 235000008209 xanthohumol Nutrition 0.000 claims abstract description 65
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 claims abstract description 65
- 239000002253 acid Substances 0.000 claims abstract description 54
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 150000007513 acids Chemical class 0.000 claims abstract description 12
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000004761 fibrosis Effects 0.000 claims abstract description 5
- 208000008589 Obesity Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000005228 liver tissue Anatomy 0.000 claims description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 abstract description 24
- 206010067125 Liver injury Diseases 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 5
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 5
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000003158 alcohol group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000004024 hepatic stellate cell Anatomy 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 235000008694 Humulus lupulus Nutrition 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- LPEPZZAVFJPLNZ-SFHVURJKSA-N sophoraflavanone B Chemical compound C1([C@@H]2CC(=O)C=3C(O)=CC(O)=C(C=3O2)CC=C(C)C)=CC=C(O)C=C1 LPEPZZAVFJPLNZ-SFHVURJKSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229930193815 Isohumulone Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000013124 brewing process Methods 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- QARXXMMQVDCYGZ-UHFFFAOYSA-N isohumulone Chemical compound CC(C)CC(=O)C1=C(O)C(O)(C(=O)CC=C(C)C)C(CC=C(C)C)C1=O QARXXMMQVDCYGZ-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- YHWNASRGLKJRJJ-UHFFFAOYSA-N sophoraflavanone B Natural products C1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC1C1=CC=C(O)C=C1 YHWNASRGLKJRJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2132—Other phenolic compounds, polyphenols
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
アルコール摂取に加えて、肥満および糖尿病は、現在、肝臓疾患の大部分の原因となっている。後者は、非アルコール性脂肪肝疾患(NAFLD)とも呼ばれる。これらの発症率は、主に食習慣が原因となっていまだに上昇している。全体としては、肝臓疾患または肝障害は、重要な経済問題となっている。
WO2008/007618A1は、肝臓疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用を開示している。これは、肥満(太り過ぎ)または糖尿病による肝臓疾患または肝障害が、長期間にわたる習慣的なキサントフモールの摂取によって効果的に抑制され得ることを見出している。さらに、これは、キサントフモールが、他の形態の肝障害に対しても好ましい効果を有することも立証している。
本発明の課題は、肝臓疾患または肝障害および/または肥満および/または糖尿病の予防および/または制御に関して、先行技術と比較して改善された活性を保証する新規物質を提供することである。本発明のもう一つの課題は、上記物質の改善された新規用途を提供することである。
本課題は、請求項1の特徴の通りの物質により解決される。本発明の適切な態様は、従属請求項において記載されている。
例示的な医薬組成物が下記に示される。
直接圧縮の粉末混合物
キサントフモール(純粋物質) 2g
イソアルファ酸 8g
微結晶性セルロース 10重量%
カルボキシメチルデンプンナトリウム 3重量%
高分散シリカ 1重量%
ステアリン酸マグネシウム 1重量%
Tablettose(ラクトース一水和物) 100重量%まで
キサントフモールを活性物質として加えた食品の例示的な組成物が下記に示される。
キサントフモール(粉末状の純粋物質) 200mlあたり150mg
イソアルファ酸 200mlあたり350mg
乳製品(クリーム状、例えばヨーグルト)
Claims (14)
- 物質、好ましくはホップに基づく物質であって、
(a)式
および
(b)異性化アルファ酸
の組み合わせを含むことを特徴とする、前記物質。 - 異性化アルファ酸が、物質中においていずれの場合にも濃縮されたまたは単離された形態で存在することを特徴とする、請求項1に記載の物質。
- キサントフモールが、物質中においていずれの場合にも濃縮されたもしくは単離された形態または合成形態で存在することを特徴とする、請求項1または2に記載の物質。
- 混合物中における異性化ホップ酸の量が、キサントフモールの量を超えていることを特徴とする、請求項1〜3のいずれか一項に記載の物質。
- 異性化ホップ酸に対するキサントフモールの量が、0.5〜10、好ましくは0.8〜8、特に好ましくは1〜5%w/wの比にあることを特徴とする、請求項4に記載の物質。
- 物質が、直接的に経口投与することができることを特徴とする、請求項1〜5のいずれか一項に記載の物質。
- 物質が、薬学的に許容し得る担体を含むことを特徴とする、請求項1〜6のいずれか一項に記載の物質。
- 肝臓組織の炎症性変化の予防および/または制御のための製剤を製造するための、請求項1〜7のいずれか一項に記載の物質の使用。
- 肝硬変または肝臓の線維化の予防および/または制御のための製剤を製造するための、請求項1〜7のいずれか一項に記載の物質の使用。
- 非アルコール性脂肪肝疾患(NAFLD)の予防および/または制御のための製剤を製造するための、請求項1〜7のいずれか一項に記載の物質の使用。
- アルコール性肝障害の予防および/または制御のための製剤を製造するための、請求項1〜7のいずれか一項に記載の物質の使用。
- 肥満および/または糖尿病の予防および/または制御のための製剤を製造するための、請求項1〜7のいずれか一項に記載の物質の使用。
- 0.001〜100mg/kg体重、好ましくは0.001〜50mg/kg体重、特に好ましくは、0.01〜10mg/kg体重の比に対応する用量での、請求項9〜12のいずれか一項に記載の物質の使用。
- 請求項1〜7のいずれか一項に記載の物質を含有することを特徴とする、食品サプリメント。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/065107 WO2017001020A1 (de) | 2015-07-02 | 2015-07-02 | Substanz auf hopfenbasis sowie verwendung der substanz |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018519342A true JP2018519342A (ja) | 2018-07-19 |
Family
ID=53546585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018500292A Pending JP2018519342A (ja) | 2015-07-02 | 2015-07-02 | ホップに基づく物質およびその物質の使用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20180193287A1 (ja) |
JP (1) | JP2018519342A (ja) |
WO (1) | WO2017001020A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111526725A (zh) * | 2017-12-27 | 2020-08-11 | 三得利控股株式会社 | 饮料及其制造方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11026897B2 (en) | 2018-08-10 | 2021-06-08 | Metagenics, Inc. | Composition of curcumagalactomannoside and hops extract |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009062584A2 (de) * | 2007-11-15 | 2009-05-22 | Hopsteiner-Hallertauer Hopfenveredelungsgesellschaft M.B.H | VERFAHREN ZUR HERSTELLUNG EINES HOPFENEXTRAKTES MIT EINEM ERHÖHTEN ANTEIL AN ISO-α-SÄUREN |
JP2010513360A (ja) * | 2006-12-22 | 2010-04-30 | ジョー. バース ウント ソーン ゲーエムベーハー ウントコー. カーゲー | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07285856A (ja) | 1994-04-21 | 1995-10-31 | Hoechst Japan Ltd | 骨粗鬆症治療剤 |
EP1543834A1 (en) | 2003-12-16 | 2005-06-22 | Biodynamics | Production of hop extracts having oestrogenic and antiproliferative bioactivity |
US20110136917A1 (en) * | 2009-08-14 | 2011-06-09 | Metaproteomics, Llc | Tetrahydro-isoalpha acid compositions and methods for weight management |
WO2011019994A1 (en) * | 2009-08-14 | 2011-02-17 | Metaproteomics, Llc | Dihydro-isoalpha acid and acacia nilotica extract based compositions and methods for weight management |
-
2015
- 2015-07-02 JP JP2018500292A patent/JP2018519342A/ja active Pending
- 2015-07-02 US US15/740,281 patent/US20180193287A1/en not_active Abandoned
- 2015-07-02 WO PCT/EP2015/065107 patent/WO2017001020A1/de active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010513360A (ja) * | 2006-12-22 | 2010-04-30 | ジョー. バース ウント ソーン ゲーエムベーハー ウントコー. カーゲー | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 |
WO2009062584A2 (de) * | 2007-11-15 | 2009-05-22 | Hopsteiner-Hallertauer Hopfenveredelungsgesellschaft M.B.H | VERFAHREN ZUR HERSTELLUNG EINES HOPFENEXTRAKTES MIT EINEM ERHÖHTEN ANTEIL AN ISO-α-SÄUREN |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111526725A (zh) * | 2017-12-27 | 2020-08-11 | 三得利控股株式会社 | 饮料及其制造方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2017001020A1 (de) | 2017-01-05 |
US20180193287A1 (en) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3682746A1 (en) | Anti-aging agent and anti-aging method | |
CA2672155C (en) | Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases | |
JP6636504B2 (ja) | 金製剤を含む、肝線維化又は肝硬変の予防又は治療用薬学的組成物 | |
EP1618875B1 (en) | Composition for inhibition or prevention of bone density lowering | |
KR101760512B1 (ko) | 혼합 생약 추출물을 포함하는 만성 염증성 질환의 예방, 치료 또는 개선용 조성물 | |
JP2005239581A (ja) | 心筋炎の予防、治療又は改善用組成物 | |
KR101685876B1 (ko) | 길경추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 | |
JP2018519342A (ja) | ホップに基づく物質およびその物質の使用 | |
JP2008260695A (ja) | 肝障害抑制剤 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
KR101688002B1 (ko) | 초음파 처리된 인삼열매 추출물을 유효성분으로 함유하는 간질환 예방 또는 치료용 조성물 | |
JP4974553B2 (ja) | アセトアルデヒド代謝促進剤 | |
KR20120112973A (ko) | 비만 또는 제 2형 당뇨의 예방 또는 치료용 조성물 | |
KR20120097080A (ko) | 백운풀 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 치료용 조성물 | |
KR20140147963A (ko) | 정제봉독을 유효성분으로 함유하는 항바이러스 또는 항종양 조성물 | |
JP6183656B2 (ja) | 非アルコール性脂肪肝抑制剤 | |
JP6320715B2 (ja) | アルコール性脂肪肝予防・治療剤 | |
JP2018087175A (ja) | 筋萎縮抑制剤 | |
CN106822152B (zh) | 一种药物组合物及其应用 | |
TW201927326A (zh) | 源自綠茶萃取物之發酵物的製造方法以及源自綠茶萃取物之麴發酵物、以及含有源自綠茶萃取物之麴發酵物的組成物 | |
JP2020515552A (ja) | 体重と体脂肪減少に用いられる組成物又は医薬品及びその用途 | |
EP3829615B1 (en) | Composition for oral administration comprising one or more cannabinoids | |
JP2021500382A (ja) | 非アルコール性脂肪肝疾患の予防または改善用組成物 | |
RU2780346C1 (ru) | Терапевтический агент против коронавируса, включающий экстракт elaeocarpus sylvestris | |
KR20130031678A (ko) | 한약재의 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20180525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180615 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190528 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200106 |